These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31754316)

  • 1. A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial.
    Blot K; Duchateau L; Lescrauwaet B; Liyanage N; Ray D; Mirakhur B; Vinik AI
    Patient Relat Outcome Meas; 2019; 10():335-343. PubMed ID: 31754316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
    Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
    Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
    Fisher GA; Wolin EM; Liyanage N; Pitman Lowenthal S; Mirakhur B; Pommier RF; Shaheen M; Vinik A;
    Oncologist; 2018 Jan; 23(1):16-24. PubMed ID: 29038234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
    Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
    Ruszniewski P; Valle JW; Lombard-Bohas C; Cuthbertson DJ; Perros P; Holubec L; Delle Fave G; Smith D; Niccoli P; Maisonobe P; Atlan P; Caplin ME;
    Dig Liver Dis; 2016 May; 48(5):552-558. PubMed ID: 26917486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study.
    Paulson S; Ray D; Aranha S; Scales A; Wang Y; Liu E
    Oncol Ther; 2022 Dec; 10(2):463-479. PubMed ID: 36136274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.
    Mirakhur B; Pavel ME; Pommier RF; Fisher GA; Phan AT; Massien C; Liyanage N; Lowenthal SP; Vinik AI
    Endocr Pract; 2018 Aug; ():. PubMed ID: 30084687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
    O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P
    Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
    N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
    Rinke A; Maintz C; Müller L; Weber MM; Lahner H; Pavel M; Saeger W; Houchard A; Ungewiss H; Petersenn S
    Exp Clin Endocrinol Diabetes; 2021 Jul; 129(7):500-509. PubMed ID: 34293802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR.
    Cella D; Beaumont JL; Hudgens S; Marteau F; Feuilly M; Houchard A; Lapuerta P; Ramage J; Pavel M; Hörsch D; Kulke MH
    Clin Ther; 2018 Dec; 40(12):2006-2020.e2. PubMed ID: 30477789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
    Dromain C; Pavel ME; Ruszniewski P; Langley A; Massien C; Baudin E; Caplin ME;
    BMC Cancer; 2019 Jan; 19(1):66. PubMed ID: 30642293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
    Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
    Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
    Ryan P; Phan AT; Adelman DT; Iwasaki M
    Clin J Oncol Nurs; 2016 Dec; 20(6):E139-E146. PubMed ID: 27857269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanreotide Autogel in the Treatment of Idiopathic Refractory Diarrhea: Results of an Exploratory, Controlled, Before and After, Open-label, Multicenter, Prospective Clinical Trial.
    Bisschops R; De Ruyter V; Demolin G; Baert D; Moreels T; Pattyn P; Verhelst H; Lepoutre L; Arts J; Caenepeel P; Ooghe P; Codden T; Maisonobe P; Petrens E; Tack J
    Clin Ther; 2016 Aug; 38(8):1902-1911.e2. PubMed ID: 27423779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.
    Wolin EM; Manon A; Chassaing C; Lewis A; Bertocchi L; Richard J; Phan AT
    J Gastrointest Cancer; 2016 Dec; 47(4):366-374. PubMed ID: 27619395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review.
    Gosain R; Gupta M; Roy AM; Strosberg J; Glaser KM; Iyer R
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of somatostatin analogs in neuroendocrine tumors.
    Sidéris L; Dubé P; Rinke A
    Oncologist; 2012; 17(6):747-55. PubMed ID: 22628056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-Related Quality of Life for Long-Acting Octreotide versus Placebo in Patients with Metastatic Midgut Neuroendocrine Tumors in the Phase 3 PROMID Trial.
    Rinke A; Neary MP; Eriksson J; Hunger M; Doan T; Karli D; Arnold R
    Neuroendocrinology; 2019; 109(2):141-151. PubMed ID: 30852564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.